We are Dedicated to
Biopharmaceutical
Research & Advancement

Generex Provides Summary of Ii-Key Hybrid Vaccine Platform

August 7, 2017

August 7, 2017 09:30 AM Eastern Daylight Time MIRAMAR, FL‐‐(BUSINESS WIRE)‐‐Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). This summary has been prepared by Dr. Jason B. Terrell, MD, the Company’s Chief Medical and Scientific Officer, as a follow-up to last week’s announcement by Generex of a clinical trial collaboration agreement between Antigen Express and Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer.

Generex Announces $115M Convertible Preferred Stock Financing; First Tranche Satisfies Emmaus Deposit

March 29, 2017

MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that it has entered into a securities purchase agreement with an institutional investor pursuant to which such investor has agreed to purchase in a private placement (the “Private Placement”) in multiple tranches 109,000 shares of the Company’s newly designed Series H Convertible Preferred Stock (the “Series H CPS”) and 6,000 shares of the Company’s newly designed Series I Convertible Preferred Stock (the “Series I CPS”) (together, the “Preferred Stock”) for an aggregate purchase price of $115,000,000 ($1,000 per share of Preferred Stock). The Preferred Stock is convertible into shares of the Company’s common stock at a conversion price of $2.50 per share (subject to adjustment under certain circumstances).

Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston

March 27, 2017

MIRAMAR, FL--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that Dr. Eric von Hofe, Ph.D., President of the Company’s wholly-owned immuno-therapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a featured speaker at the Cambridge Healthtech Institute’s second annual Oligonucleotide & Peptide Therapeutics conference (OPT Boston) (www.optcongress.com) being held in Cambridge, MA March 27 – 29, 2017.

Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer

July 31, 2017

July 31, 2017 09:30 AM Eastern Daylight Time MIRAMAR, FL‐‐(BUSINESS WIRE)‐‐Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.